NASDAQ:CATB - Catabasis Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $39.75
  • Forecasted Upside: 634.75 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$5.41
▼ -0.45 (-7.68%)
1 month | 3 months | 12 months
Get New Catabasis Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CATB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CATB

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$39.75
▲ +634.75% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Catabasis Pharmaceuticals in the last 3 months. The average price target is $39.75, with a high forecast of $60.00 and a low forecast of $15.00. The average price target represents a 634.75% upside from the last price of $5.41.
Buy
The current consensus among 3 contributing investment analysts is to buy stock in Catabasis Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/30/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/29/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/21/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/21/2020

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/1/2020HC WainwrightInitiated CoverageBuy$24.00 ➝ $24.00High
i
Rating by J. Pantginis at HC Wainwright
9/15/2020OppenheimerReiterated RatingBuy$60.00High
i
8/20/2020WedbushReiterated RatingBuy$15.00Low
i
Rating by Liana Moussatos at Wedbush
6/11/2020WedbushReiterated RatingBuy$15.00Medium
i
Rating by Liana Moussatos at Wedbush
4/19/2020WedbushReiterated RatingBuy$15.00Medium
i
Rating by Liana Moussatos at Wedbush
3/10/2020OppenheimerReiterated RatingBuy$60.00High
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
3/10/2020WedbushReiterated RatingBuy$15.00High
i
Rating by Liana Moussatos at Wedbush
1/8/2020WedbushReiterated RatingBuy$18.00Medium
i
Rating by Liana Moussatos at Wedbush
12/16/2019WedbushReiterated RatingBuy$18.00Low
i
Rating by Liana Moussatos at Wedbush
11/8/2019CitigroupLower Price Target$72.00 ➝ $60.00High
i
7/29/2019WedbushReiterated RatingOutperform$18.00High
i
Rating by Liana Moussatos at Wedbush
6/24/2019WedbushSet Price TargetBuy$18.00High
i
Rating by Liana Moussatos at Wedbush
5/17/2019WedbushReiterated RatingBuy$18.00Medium
i
Rating by Liana Moussatos at Wedbush
3/18/2019WedbushReiterated RatingBuy$20.00Low
i
Rating by Liana Moussatos at Wedbush
1/29/2019WedbushSet Price TargetBuy$28.00N/A
i
Rating by Liana Moussatos at Wedbush
1/14/2019OppenheimerBoost Price TargetOutperform$7.00 ➝ $77.00High
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
11/14/2018OppenheimerSet Price TargetBuy$70.00Low
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
8/10/2018CitigroupLower Price TargetBuy ➝ Buy$25.00 ➝ $15.00Low
i
8/9/2018WedbushSet Price TargetBuy$30.00Low
i
Rating by Liana Moussatos at Wedbush
3/20/2018WedbushBoost Price TargetOutperform ➝ Outperform$50.00 ➝ $60.00Low
i
2/14/2018WedbushReiterated RatingOutperform$50.00 ➝ $40.00High
i
12/15/2017WedbushReiterated RatingOutperform$40.00Low
i
11/20/2017CitigroupUpgradeNeutral ➝ Buy$30.00N/A
i
Rating by Joel Beatty at Citigroup Inc.
10/6/2017CowenReiterated RatingMarket Perform$20.00N/A
i
10/5/2017CIBCReiterated RatingOutperform ➝ Outperform$40.00 ➝ $70.00N/A
i
10/5/2017CitigroupSet Price TargetHold$15.00 ➝ $35.00N/A
i
10/5/2017OppenheimerBoost Price TargetOutperform$40.00 ➝ $70.00N/A
i
9/29/2017CitigroupReiterated RatingHold$15.00Low
i
8/15/2017OppenheimerLower Price TargetOutperform$90.00 ➝ $40.00High
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
8/14/2017HC WainwrightBoost Price TargetBuy$80.00 ➝ $90.00Medium
i
6/21/2017WedbushReiterated RatingOutperform$40.00High
i
5/15/2017WedbushReiterated RatingOurperform$40.00High
i
5/15/2017OppenheimerReiterated RatingOutperform$110.00 ➝ $90.00Medium
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
4/26/2017WedbushReiterated RatingOutperform$40.00Low
i
3/21/2017HC WainwrightReiterated RatingBuy$140.00 ➝ $80.00Low
i
Rating by C. Werther at HC Wainwright
3/20/2017WedbushReiterated RatingOutperform$40.00High
i
3/18/2017OppenheimerSet Price TargetBuy$110.00High
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
3/14/2017WedbushReiterated RatingOutperform$40.00Medium
i
2/2/2017WedbushReiterated RatingOutperform$150.00 ➝ $40.00N/A
i
2/1/2017CitigroupDowngradeBuy ➝ NeutralN/A
i
2/1/2017CowenDowngradeOutperform ➝ Market Perform$40.00N/A
i
1/31/2017OppenheimerSet Price TargetBuy$180.00 ➝ $110.00N/A
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
1/6/2017WedbushReiterated RatingOutperform$150.00N/A
i
12/22/2016HC WainwrightInitiated CoverageBuy$140.00N/A
i
Rating by C. Werther at HC Wainwright
12/7/2016WedbushReiterated RatingOutperform$150.00N/A
i
11/14/2016WedbushReiterated RatingOutperform$150.00 ➝ $170.00N/A
i
10/13/2016WedbushReiterated RatingOutperform$170.00N/A
i
9/29/2016WedbushReiterated RatingOutperform$170.00N/A
i
8/12/2016WedbushReiterated RatingOutperform$170.00N/A
i
Rating by Liana Moussatos at Wedbush
6/8/2016CowenReiterated RatingBuyN/A
i
Rating by Phil Nadeau at Cowen Inc
6/7/2016WedbushReiterated RatingOutperform$270.00 ➝ $170.00N/A
i
Rating by Liana Moussatos at Wedbush
5/25/2016OppenheimerReiterated RatingOutperform$280.00N/A
i
Rating by Christopher Marai at Oppenheimer Holdings Inc.
5/14/2016CowenReiterated RatingBuyN/A
i
Rating by Phil Nadeau at Cowen Inc
5/14/2016OppenheimerReiterated RatingBuyN/A
i
Rating by Christopher Marai at Oppenheimer Holdings Inc.
5/13/2016WedbushReiterated RatingOutperform$270.00N/A
i
Rating by Liana Moussatos at Wedbush
3/28/2016WedbushReiterated RatingOutperform$270.00N/A
i
Rating by Liana Moussatos at Wedbush
3/22/2016CitigroupLower Price TargetBuy$210.00 ➝ $160.00N/A
i
3/7/2016CowenReiterated RatingOutperform$300.00N/A
i
3/2/2016WedbushReiterated RatingOutperform$270.00N/A
i
Rating by Liana Moussatos at Wedbush
1/19/2016WedbushReiterated RatingOutperform$270.00N/A
i
Rating by Liana Moussatos at Wedbush
1/4/2016WedbushReiterated RatingOutperform$270.00N/A
i
Rating by Liana Moussatos at Wedbush
12/11/2015WedbushInitiated CoverageBuyN/A
i
Rating by Liana Moussatos at Wedbush
12/10/2015WedbushReiterated RatingOutperform$270.00N/A
i
Rating by Liana Moussatos at Wedbush
(Data available from 10/21/2015 forward)
Catabasis Pharmaceuticals logo
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.
Read More

Today's Range

Now: $5.41
$5.27
$5.86

50 Day Range

MA: $6.38
$5.96
$7.00

52 Week Range

Now: $5.41
$2.74
$8.59

Volume

311,637 shs

Average Volume

233,057 shs

Market Capitalization

$103.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.64